Pharma BD Deal Intelligence
Laboratoires Pierre Fabre and XtalPi Holdings entered an AI-driven drug discovery collaboration spanning oncology and potentially dermatology and rare diseases. XtalPi will use its integrated AI and robotics platform to de novo design and deliver novel small-molecule therapeutics against undisclosed targets; Pierre Fabre contributes disease biology, discovery, translational research and clinical development expertise, selecting compounds and taking responsibility for subsequent clinical and commercial development. The agreement includes an upfront payment, multiple milestone payments and downstream economic participation; neither party disclosed financial terms.